Ep. 19 Intravenous Antiplatelet Therapy in Acute Coronary Syndrome with Dr. Hayder Hashim

Preventing problems before they aggregate, P2Y12 inhibitor style! In this episode of the BackTable Cardiology Podcast, interventional cardiologist from MedStar Washington Hospital Center joins host Dr. Hady Lichaa for practical insights and key takeaways on antiplatelet use in the setting of acute coronary syndrome (ACS).---This podcast is supported by an educational grant from Cheisi.---SYNPOSISDr. Hashim talks through the use of intravenous antiplatelet therapies, specifically cangrelor, for managing acute coronary syndrome. Their discussion explores the pharmacokinetics, clinical advantages, and potential future applications of IV P2Y12 inhibitors. Dr. Hashim shares his wealth of experience in antiplatelet case studies and shares best practices when transitioning patients from IV to oral antiplatelet therapies. The conversation focuses on enhancing patient outcomes, minimizing complications, and lessons learned from different clinical scenarios.---TIMESTAMPS00:00 - Introduction03:31 - Intravenous Antiplatelet Therapies Overview06:01 - The Importance of IV P2Y12 Inhibitors09:15 - Guidelines and Usage of GP IIb/IIIa Inhibitors11:30 - Advantages of IV P2Y12 Inhibitors in Clinical Practice14:32 - Practical Applications and Case Studies24:42 - Cost Effectiveness, Hospital Administration, Financial Implications28:20 - Contraindications and Practical Considerations30:09 - Loading and Infusion Protocols34:58 - Bridging for Surgery39:48 - Anticoagulation and Heparin Goals48:55 - Future of IV Antiplatelet Therapy50:44 - Conclusion---RESOURCESAssociation of 2B3A inhibition with new antiplatelet regimens in the setting of acute coronary syndromes: a meta-analysis of randomized controlled trialshttps://academic.oup.com/eurheartj/article-abstract/34/suppl_1/P4861/2862796 Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events - CHAMPION PHOENIXhttps://www.nejm.org/doi/full/10.1056/NEJMoa1300815 Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trialhttps://pubmed.ncbi.nlm.nih.gov/38237620/ Abstract 4370674: Cangrelor Versus Oral P2Y12 Inhibitors During PCI in Cardiogenic Shock and Cardiac Arrest: A Systematic Review and Meta-analysishttps://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4370674Dr. Hayder Hashimhttps://www.medstarhealth.org/doctors/hayder-hashim-md Dr. Hady Lichaahttps://healthcare.ascension.org/find-care/provider/1336267533/hady-lichaa